Cargando…

The outcomes of dexmedetomidine and calcitriol on flap viability

PURPOSE: To evaluate protective effects of dexmedetomidine, calcitriol and their combination. METHODS: Forty Wistar-albino rats were divided into 4 groups; group of Sham (Group Sham); group of dexmedetomidine (Group DEX); group of calcitriol (Group CAL) and group of dexmedetomidineandcalcitriol (Gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotanoğlu, Mustafa Sırrı, Akbulut, Aylin, Gürsoy, Koray, Koca, Gökhan, Özcan, Namık, Yumuşak, Nihat, Şenes, Mehmet, Kırtıl, Gül, Korkmaz, Meliha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531053/
https://www.ncbi.nlm.nih.gov/pubmed/33027360
http://dx.doi.org/10.1590/s0102-865020200090000003
_version_ 1783589687068196864
author Kotanoğlu, Mustafa Sırrı
Akbulut, Aylin
Gürsoy, Koray
Koca, Gökhan
Özcan, Namık
Yumuşak, Nihat
Şenes, Mehmet
Kırtıl, Gül
Korkmaz, Meliha
author_facet Kotanoğlu, Mustafa Sırrı
Akbulut, Aylin
Gürsoy, Koray
Koca, Gökhan
Özcan, Namık
Yumuşak, Nihat
Şenes, Mehmet
Kırtıl, Gül
Korkmaz, Meliha
author_sort Kotanoğlu, Mustafa Sırrı
collection PubMed
description PURPOSE: To evaluate protective effects of dexmedetomidine, calcitriol and their combination. METHODS: Forty Wistar-albino rats were divided into 4 groups; group of Sham (Group Sham); group of dexmedetomidine (Group DEX); group of calcitriol (Group CAL) and group of dexmedetomidineandcalcitriol (Group DEX-CAL). Photographic analysis was used for macroscopic analysis and perfusion analyses were evaluated by scintigraphy. Additionally, tissue malondialdehyde (MDA) and total oxidant status (TOS) and total antioxidant activity (TAS) were recorded and oxidative stress index (OSI) was calculated. Each flap was assessed by histopathology. RESULTS: Compared to Group Sham, the viable flap areas were higher in all treatment groups both by photographic image analyses and perfusion analyses (p<0.05). Group DEX-CAL had the highest viable flap percentage both in scintigraphic and photographic analyses; whereas Group Sham had the lowest viable flap percentage. Similarly, TAS and MDA levels were elevated and TOS levels were declined in all treatment groups compared to Group Sham (p<0.005). Histopathological analysis at flap demarcation zone confirmed neovascularization was significantly higher and edema, necrosis and inflammation were significantly lower in all treatment groups compared to Group Sham. CONCLUSION: The outcomes show that additional premedication with either dexmedetomidine or calcitriol or their combination reduces ischemia-reperfusion injury of flap area and show significant increase in the percentage of viable flap tissue.
format Online
Article
Text
id pubmed-7531053
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
record_format MEDLINE/PubMed
spelling pubmed-75310532020-10-13 The outcomes of dexmedetomidine and calcitriol on flap viability Kotanoğlu, Mustafa Sırrı Akbulut, Aylin Gürsoy, Koray Koca, Gökhan Özcan, Namık Yumuşak, Nihat Şenes, Mehmet Kırtıl, Gül Korkmaz, Meliha Acta Cir Bras Original Article PURPOSE: To evaluate protective effects of dexmedetomidine, calcitriol and their combination. METHODS: Forty Wistar-albino rats were divided into 4 groups; group of Sham (Group Sham); group of dexmedetomidine (Group DEX); group of calcitriol (Group CAL) and group of dexmedetomidineandcalcitriol (Group DEX-CAL). Photographic analysis was used for macroscopic analysis and perfusion analyses were evaluated by scintigraphy. Additionally, tissue malondialdehyde (MDA) and total oxidant status (TOS) and total antioxidant activity (TAS) were recorded and oxidative stress index (OSI) was calculated. Each flap was assessed by histopathology. RESULTS: Compared to Group Sham, the viable flap areas were higher in all treatment groups both by photographic image analyses and perfusion analyses (p<0.05). Group DEX-CAL had the highest viable flap percentage both in scintigraphic and photographic analyses; whereas Group Sham had the lowest viable flap percentage. Similarly, TAS and MDA levels were elevated and TOS levels were declined in all treatment groups compared to Group Sham (p<0.005). Histopathological analysis at flap demarcation zone confirmed neovascularization was significantly higher and edema, necrosis and inflammation were significantly lower in all treatment groups compared to Group Sham. CONCLUSION: The outcomes show that additional premedication with either dexmedetomidine or calcitriol or their combination reduces ischemia-reperfusion injury of flap area and show significant increase in the percentage of viable flap tissue. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020-09-30 /pmc/articles/PMC7531053/ /pubmed/33027360 http://dx.doi.org/10.1590/s0102-865020200090000003 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kotanoğlu, Mustafa Sırrı
Akbulut, Aylin
Gürsoy, Koray
Koca, Gökhan
Özcan, Namık
Yumuşak, Nihat
Şenes, Mehmet
Kırtıl, Gül
Korkmaz, Meliha
The outcomes of dexmedetomidine and calcitriol on flap viability
title The outcomes of dexmedetomidine and calcitriol on flap viability
title_full The outcomes of dexmedetomidine and calcitriol on flap viability
title_fullStr The outcomes of dexmedetomidine and calcitriol on flap viability
title_full_unstemmed The outcomes of dexmedetomidine and calcitriol on flap viability
title_short The outcomes of dexmedetomidine and calcitriol on flap viability
title_sort outcomes of dexmedetomidine and calcitriol on flap viability
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531053/
https://www.ncbi.nlm.nih.gov/pubmed/33027360
http://dx.doi.org/10.1590/s0102-865020200090000003
work_keys_str_mv AT kotanoglumustafasırrı theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT akbulutaylin theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT gursoykoray theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT kocagokhan theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT ozcannamık theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT yumusaknihat theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT senesmehmet theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT kırtılgul theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT korkmazmeliha theoutcomesofdexmedetomidineandcalcitriolonflapviability
AT kotanoglumustafasırrı outcomesofdexmedetomidineandcalcitriolonflapviability
AT akbulutaylin outcomesofdexmedetomidineandcalcitriolonflapviability
AT gursoykoray outcomesofdexmedetomidineandcalcitriolonflapviability
AT kocagokhan outcomesofdexmedetomidineandcalcitriolonflapviability
AT ozcannamık outcomesofdexmedetomidineandcalcitriolonflapviability
AT yumusaknihat outcomesofdexmedetomidineandcalcitriolonflapviability
AT senesmehmet outcomesofdexmedetomidineandcalcitriolonflapviability
AT kırtılgul outcomesofdexmedetomidineandcalcitriolonflapviability
AT korkmazmeliha outcomesofdexmedetomidineandcalcitriolonflapviability